BD SurePath™ liquid-based Pap Test



The time is right for the BD SurePath™ test
.

BD SurePath™ liquid-based Pap test  

“Comparison of SurePath® liquid-based Pap test to Conventional Pap test in a Multi-site Direct-to-Vial Study”
M Fremont-Smith, J Marino, B Griffin, L Spencer, D Bolick,
Cancer Cytopathology; October 25,2004, Vol 102(5), pp. 269-279.


BACKGROUND
Split-sample clinical trials for liquid-based Papanicolaou (Pap) smears demonstrated that the liquid-based Pap smear was a safe and effective replacement for the conventional Pap smear. However, clinical intended use of liquid-based technology employs direct-to-vial collection methods. The current study compared the cytologic detection rates of the liquid-based Pap smear with conventional Pap smears in a direct-to-vial study performed at three clinical sites.

METHODS
Data from 58,580 prospective SurePath® slides and 58,988 historic conventional slides were collected. Results were statistically compared with regard to disease prevalence and adequacy to include biopsy follow-up data for conven- tional and SurePath® Pap tests.

RESULTS
The SurePath® method was found to provide a statistically significantly greater detection rate for clinically important categories of high-grade squamous intraepithelial lesion (HSIL+) and low-grade squamous intraepithelial lesion (LSIL+) (64% and 107%, respectively; P <0.00001 for each lesion) compared with conventional slides. The clinical significance of increased cytologic detection using SurePath® was supported by biopsy data that essentially demonstrated concordance with regard to biopsy interpretation for HSIL+ (P = 0.9105 at Site 1; P = 1.0000 at Site 2; and P = 1.0000 at Site 3) and LSIL (P = 0.6966 at Site 1; P = 0.8052 at Site 2; and P = 1.00 at Site 3). The detection rate of atypical squamous cells of undetermined significance (ASCUS) was found to be significantly increased (75.12%; P < 0.00001). A statistically significantly lower proportion of unsatisfactory slides using the SurePath® test compared with conventional slides was noted (-58%; P 0.00001). The ASCUS/LSIL ratio was found to be reduced overall when using SurePath® (-28.9%), regardless of whether the study sites were combined or considered individually. The rate of false-negative results noted with SurePath® (10.43%) and conventional slides (12.97%) was essentially equivalent.

CONCLUSIONS
The SurePath® Pap test was found to outperform conventional slides in the detection of HSIL+ and LSIL+ cytologic lesions of the cervix and reduced the number of unsatisfactory diagnoses. The HSIL+ advantage for SurePath® is not limited to HSIL but appears to extend to carcinoma as well.

 
 
Clinical News

Independent study on the effect of blood on cellularity of cervical sample.

BD SurePath™ Pap test Direct to Vial Clinical Study.

Study shows that rinsing sampling devices does not transfer all the sampled cervical cells to the vial for analysis.


 

Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD